1079355-01-3

Upstream product

• 5090-16-4 5-methylhepta-3-en-2-one 
• 1357010-74-2 1-amino-3-(1-methylpropyl)-5-methyl-1H-pyrrole-2-carboxylic acid N-methylamide 
• 19447-00-8 4-methoxy-2,6-dimethylbenzylaldehyde 
• 1079352-24-1 3-(1-methylpropyl)-5-methyl-1H-pyrrole 
• 1079352-23-0 ethyl 3-sec-butyl-5-methyl-1H-pyrrole-2-carboxylate 
• 1079352-21-8 ethyl 4-methyl-2-nitro-3-(2-oxopropyl)hexanoate 
• 1357010-73-1 3-(1-methylpropyl)-5-methyl-1H-pyrrole-2-caboxylic acid methylamide 
• 1079352-22-9 ethyl 2-(hydroxyimino)-4-methyl-3-(2-oxopropyl)hexanoate 

Relevant academic research and scientific papers

Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists

To identify structurally novel corticotropin-releasing factor 1 (CRF 1) receptor antagonists, a series of bicyclic core analogs pyrrolo[1,2-b]pyridazines and pyrrolo[2,1-f]triazin-4(3H)-ones, which were designed based on a monocyclic core antag

BICYCLIC HETEROCYCLIC COMPOUND

In the prevention and/or treatment of a neuropsychiatric disease or a peripheral organ disease and the like, a pharmaceutical which comprises a compound having CRF antagonistic activity as an active ingredient is provided. A compound of a formula (I): wherein R1 represents a C3-10 branched alkyl group which may be substituted; R2 represents a hydrogen atom or a C1-4 alkyl group which may be substituted; R3 represents a C1-4 alkyl group which may be substituted or a halogen atom; R4 represents a C1-4 alkyl group which may be substituted; and ring 1 represents a cyclic group which has planarity and may have a substituent group, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a medicinal component having CRF antagonistic activity for the prevention and/or treatment of a neuropsychiatric disease, a peripheral organ disease and the like.